124 related articles for article (PubMed ID: 26744529)
1. A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.
Zhong H; Davis A; Ouzounova M; Carrasco RA; Chen C; Breen S; Chang YS; Huang J; Liu Z; Yao Y; Hurt E; Moisan J; Fung M; Tice DA; Clouthier SG; Xiao Z; Wicha MS; Korkaya H; Hollingsworth RE
Cancer Res; 2016 Jan; 76(2):480-90. PubMed ID: 26744529
[TBL] [Abstract][Full Text] [Related]
2. Resistance to Anti-VEGF Therapy Mediated by Autocrine IL6/STAT3 Signaling and Overcome by IL6 Blockade.
Eichten A; Su J; Adler AP; Zhang L; Ioffe E; Parveen AA; Yancopoulos GD; Rudge J; Lowy I; Lin HC; MacDonald D; Daly C; Duan X; Thurston G
Cancer Res; 2016 Apr; 76(8):2327-39. PubMed ID: 26921327
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor efficacy against the EGFRvIII+HER2+ breast cancers by combining trastuzumab with anti-EGFRvIII antibody CH12.
Xu W; Bi Y; Zhang J; Kong J; Jiang H; Tian M; Li K; Wang B; Chen C; Song F; Pan X; Shi B; Kong X; Gu J; Cai X; Li Z
Oncotarget; 2015 Nov; 6(36):38840-53. PubMed ID: 26474285
[TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells.
Mao Y; Zhang Y; Qu Q; Zhao M; Lou Y; Liu J; huang O; Chen X; Wu J; Shen K
Mol Biosyst; 2015 Apr; 11(4):1029-40. PubMed ID: 25648538
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
7. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts.
du Manoir JM; Francia G; Man S; Mossoba M; Medin JA; Viloria-Petit A; Hicklin DJ; Emmenegger U; Kerbel RS
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):904-16. PubMed ID: 16467105
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop.
Yang Z; Guo L; Liu D; Sun L; Chen H; Deng Q; Liu Y; Yu M; Ma Y; Guo N; Shi M
Oncotarget; 2015 Mar; 6(7):5072-87. PubMed ID: 25669984
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness.
Saidi A; Hagedorn M; Allain N; Verpelli C; Sala C; Bello L; Bikfalvi A; Javerzat S
Int J Cancer; 2009 Sep; 125(5):1054-64. PubMed ID: 19431143
[TBL] [Abstract][Full Text] [Related]
10. IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis.
Brooks GD; McLeod L; Alhayyani S; Miller A; Russell PA; Ferlin W; Rose-John S; Ruwanpura S; Jenkins BJ
Cancer Res; 2016 Feb; 76(4):866-76. PubMed ID: 26744530
[TBL] [Abstract][Full Text] [Related]
11. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.
Damiano V; Garofalo S; Rosa R; Bianco R; Caputo R; Gelardi T; Merola G; Racioppi L; Garbi C; Kandimalla ER; Agrawal S; Tortora G
Clin Cancer Res; 2009 Nov; 15(22):6921-30. PubMed ID: 19903791
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
13. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
[TBL] [Abstract][Full Text] [Related]
14. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
[TBL] [Abstract][Full Text] [Related]
15. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
16. β2-AR signaling controls trastuzumab resistance-dependent pathway.
Liu D; Yang Z; Wang T; Yang Z; Chen H; Hu Y; Hu C; Guo L; Deng Q; Liu Y; Yu M; Shi M; Du N; Guo N
Oncogene; 2016 Jan; 35(1):47-58. PubMed ID: 25798840
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment.
Carbone C; Tamburrino A; Piro G; Boschi F; Cataldo I; Zanotto M; Mina MM; Zanini S; Sbarbati A; Scarpa A; Tortora G; Melisi D
Anticancer Drugs; 2016 Jan; 27(1):29-40. PubMed ID: 26473526
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
